A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

A newly approved drug for type 2 diabetes and kidney disease, sotagliflozin, has shown remarkable benefits in reducing the ...

SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in older adults with type 2 diabetes ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

sodium-glucose transporter 2 (SGLT2) inhibitors — these reduce the amount of glucose reabsorbed by the kidneys, meaning that it is excreted in the urine. A meta-analysis, published in the ...

SGLT-2 inhibitors canagliflozin, empagliflozin, and dapagliflozin showed overall comparable effectiveness on cardiovascular outcomes in T2D.

The study revealed a lower risk of nephrolithiasis with SGLT2 inhibitors than DPP4 inhibitors in both stone never-formers and ...